Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by chronic oligoanovulation and hyperandrogenism and associated with insulin resistance, type 2 diabetes, and cardiovascular risk. In recent years, genetic studies have linked PCOS to a dinucleotide marker D19S884 in the fibrillin 3 gene. Fibrillins make up the major component of microfibrils in the extracellular matrix (ECM) and interact with molecules in the ECM to regulate transforming growth factor β (TGF-β) signaling. Therefore, variations in fibrillin 3 and subsequent dysregulation of TGF-β may contribute to the pathogenesis of PCOS. Here, we review the evidence from genetic studies supporting the role of TGF-β in PCOS and describe how TGF-β dysregulation may contribute to (1) the fetal origins of PCOS, (2) reproductive abnormalities in PCOS, and (3) cardiovascular and metabolic abnormalities in PCOS.
Raja-KhanNLegroRS. Diagnosis and management of polycystic ovary syndrome. J Clin Outcomes Manage. 2005;12(4):218–227.
2.
UrbanekMLegroRSDriscollDAThirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999;96(15):8573–8578.
3.
UrbanekMWoodroffeAEwensKGCandidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab. 2005;90(12):6623–6629.
4.
StewartDRDombroskiBAUrbanekMFine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J Clin Endocrinol Metab. 2006;91(10):4112–4117.
5.
FornoniALenzOStrikerLJStrikerGE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes. 2003;52(10):2594–2602.
6.
FerrandPEParrySSammelMA polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. Mol Hum Reprod. 2002;8(5):494–501.
7.
FenechAGBillingtonCKSwanCNovel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol. 2004;30(5):678–686.
8.
Dolan-O'KeefeMChowVMonnierJVisnerGANickHS. Transcriptional regulation and structural organization of the human cytosolic phospholipase A(2) gene. Am J Physiol Lung Cell Mol Physiol. 2000;278(4):L649–657.
9.
HuangXVaagACarlssonEHanssonMAhrenBGroopL. Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes. Diabetes. 2003;52(9):2411–2418.
10.
HataRAkaiJKimuraAIshikawaOKuwanaMShinkaiH. Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun. 2000;272(1):36–40.
11.
RothenburgSKoch-NolteFRichAHaagF. A polymorphic dinucleotide repeat in the rat nucleolin gene forms Z-DNA and inhibits promoter activity. Proc Natl Acad Sci U S A. 2001;98(16):8985–8990.
12.
GebhardtFZankerKSBrandtB. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999;274(19):13176–13180.
13.
GabelliniN. A polymorphic GT repeat from the human cardiac Na+Ca2+ exchanger intron 2 activates splicing. Eur J Biochem. 2001;268(4):1076–1083.
14.
HuiJStanglKLaneWSBindereifA. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol. 2003;10(1):33–37.
15.
HuiJReitherGBindereifA. Novel functional role of CA repeats and hnRNP L in RNA stability. RNA. 2003;9(8):931–936.
16.
StanglKCascorbiILauleMHigh CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics. 2000;10(2):133–140.
17.
GelbBD. Marfan's syndrome and related disorders--more tightly connected than we thought. N Engl J Med. 2006;355(8):841–844.
JordanCDBohlingSDCharbonneauNLSakaiLY. Fibrillins in adult human ovary and polycystic ovary syndrome: is fibrillin-3 affected in PCOS?J Histochem Cytochem. 2010;58(10):903–915.
WeltCKTaylorAEFoxJMesserlianGMAdamsJMSchneyerAL. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. J Clin Endocrinol Metab. 2005;90(10):5582–5587.
25.
FlemingRHarborneLMacLaughlinDTMetformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril. 2005;83(1):130–136.
26.
Eldar-GevaTSpitzIMGroomeNPMargaliothEJHomburgR. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod. 2001;16(12):2552–2556.
27.
KevenaarMELavenJSFongSLA functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. J Clin Endocrinol Metab. 2008;93(4):1310–1316.
28.
GlisterCRichardsSLKnightPG. Bone morphogenetic proteins (BMP) -4, -6, and -7 potently suppress basal and luteinizing hormone-induced androgen production by bovine theca interna cells in primary culture: could ovarian hyperandrogenic dysfunction be caused by a defect in thecal BMP signaling?Endocrinology. 2005;146(4):1883–1892.
29.
IngmanWVRobkerRLWoittiezKRobertsonSA. Null mutation in transforming growth factor beta1 disrupts ovarian function and causes oocyte incompetence and early embryo arrest. Endocrinology. 2006;147(2):835–845.
30.
UrbanekMWuXVickeryKRAllelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85(12):4455–4461.
31.
HughesdonPE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called “hyperthecosis”. Obstet Gynecol Surv. 1982;37(2):59–77.
32.
UrbanekM. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(2):103–111.
33.
UrbanekMSamSLegroRSDunaifA. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab. 2007;92(11):4191–4198.
34.
YalamanchiSKSamSCardenasMOHoladayLWUrbanekMDunaifA. Association of fibrillin-3 and transcription factor-7-like 2 gene variants with metabolic phenotypes in PCOS. Obesity (Silver Spring). 2012;20(6):1273–1278.
35.
NormanRJMilnerCRGroomeNPRobertsonDM. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod. 2001;16(4):668–672.
36.
VilluendasGEscobar-MorrealeHFTosiFSanchoJMoghettiPSan MillanJL. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil Steril. 2003;79(1):219–220.
37.
TucciSFutterweitWConcepcionESEvidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab. 2001;86(1):446–449.
38.
ProdoehlMJHatzirodosNIrving-RodgersHFGenetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Mol Hum Reprod. 2009;15(12):829–841.
39.
HuangXVaagACarlssonEHanssonMAhrenBGroopL. Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes. Diabetes. 2003;52(9):2411–2418.
40.
LiaoWXRoyACNgSC. Preliminary investigation of follistatin gene mutations in women with polycystic ovary syndrome. Mol Hum Reprod. 2000;6(7):587–590.
41.
JonesMRWilsonSGMullinBHMeadRWattsGFStuckeyBG. Polymorphism of the follistatin gene in polycystic ovary syndrome. Mol Hum Reprod. 2007;13(4):237–241.
42.
SproulKJonesMRMathurRAzzizRGoodarziMO. Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG. 2010;117(6):756–760.
43.
KevenaarMEThemmenAPvan KerkwijkAJVariants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. Hum Reprod. 2009;24(1):241–249.
44.
ChenZJZhaoHHeLGenome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43(1):55–59.
45.
ProdoehlMJIrving-RodgersHFBonnerWMFibrillins and latent TGFbeta binding proteins in bovine ovaries of offspring following high or low protein diets during pregnancy of dams. Mol Cell Endocrinol. 2009;307(1-2):133–141.
46.
HatzirodosNBayneRAIrving-RodgersHFLinkage of regulators of TGF-beta activity in the fetal ovary to polycystic ovary syndrome. FASEB J. 2011;25(7):2256–2265.
47.
RamirezFPereiraL. The fibrillins. Int J Biochem Cell Biol. 1999;31(2):255–259.
TodorovicVRifkinDB. LTBPs, more than just an escort service. J Cell Biochem. 2012;113(2):410–418.
50.
OnoRNSengleGCharbonneauNLLatent transforming growth factor beta-binding proteins and fibulins compete for fibrillin-1 and exhibit exquisite specificities in binding sites. J Biol Chem. 2009;284(25):16872–16881.
51.
LeClairRLindnerV. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor beta signaling. Trends Cardiovasc Med. 2007;17(6):202–205.
52.
ChristnerPJAyiteyS.Extracellular matrix containing mutated fibrillin-1 (Fbn1) down regulates Col1a1, Col1a2, Col3a1, Col5a1, and Col5a2 mRNA levels in Tsk/+ and Tsk/Tsk embryonic fibroblasts. Amino Acids. 2006;30(4):445–451.
53.
VerrecchiaFMauvielA. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal. 2004;16(8):873–880.
54.
KhanRSheppardR. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118(1):10–24.
55.
ChapmanHA. Disorders of lung matrix remodeling. J Clin Invest. 2004;113(2):148–157.
56.
HetzelMBachemMAndersDTrischlerGFaehlingM. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183(4):225–237.
57.
KisselevaTBrennerDA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007;22(suppl 1):S73–S78.
58.
Prud'hommeGJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest. 2007;87(11):1077–1091.
59.
BottingerEP. TGF-beta in renal injury and disease. Semin Nephrol. 2007;27(3):309–320.
60.
SteinIFLeventhalML. Amenorhea associated with bilateral polcystic ovaries. American Journal of Obstetrics and Gynaecology. 1935;29:181–191.
61.
NelsonVLLegroRSStraussJF 3rd McAllisterJM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13(6):946–957.
62.
NelsonVLQinKNRosenfieldRLThe biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(12):5925–5933.
63.
Veiga-LopezAYeWPhillipsDJHerkimerCKnightPGPadmanabhanV. Developmental programming: deficits in reproductive hormone dynamics and ovulatory outcomes in prenatal, testosterone-treated sheep. Biol Reprod. 2008;78(4):636–647.
64.
AbbottDHBarnettDKBrunsCMDumesicDA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?Hum Reprod Update. 2005;11(4):357–374.
65.
WebberLJStubbsSStarkJFormation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–1021.
66.
ForsdikeRAHardyKBullLDisordered follicle development in ovaries of prenatally androgenized ewes. J Endocrinol. 2007;192(2):421–428.
67.
HagueWMAdamsJRoddaCThe prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf). 1990;33(4):501–510.
68.
BarnesRBRosenfieldRLEhrmannDAOvarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994;79(5):1328–1333.
69.
DaviesMJMarchWAWillsonKJGilesLCMooreVM. Birthweight and thinness at birth independently predict symptoms of polycystic ovary syndrome in adulthood. Hum Reprod. 2012;27(5):1475–1480.
70.
XuNKwonSAbbottDHEpigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One. 2011;6(11):e27286.
71.
SabatierLMiosgeNHubmacherDLinGDavisECReinhardtDP. Fibrillin-3 expression in human development. Matrix Biol. 2011;30(1):43–52.
72.
TromblyDJWoodruffTKMayoKE. Roles for transforming growth factor beta superfamily proteins in early folliculogenesis. Semin Reprod Med. 2009;27(1):14–23.
73.
Raja-KhanNKunselmanARDemersLMEwensKGSpielmanRSLegroRS. A variant in the fibrillin-3 gene is associated with TGF-beta and inhibin B levels in women with polycystic ovary syndrome. Fertil Steril. 2010;94(7):2916–2919.
74.
KaurSArcherKJDeviMGKriplaniAStraussJF 3rd SinghR. Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: identification of susceptibility gene sets through network analysis. J Clin Endocrinol Metab. 2012;97(10):E2016–E2021.
75.
BalenAHLavenJSTanSLDewaillyD. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9(6):505–514.
76.
LegroRSChiuPKunselmanARBentleyCMDodsonWCDunaifA. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab. 2005;90(5):2571–2579.
77.
WoodruffTKSheaLD. A new hypothesis regarding ovarian follicle development: ovarian rigidity as a regulator of selection and health. J Assist Reprod Genet. 2011;28(1):3–6.
78.
FarquharCLilfordRJMarjoribanksJVandekerckhoveP.Laparoscopic “drilling” by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2005;(3):CD001122.
79.
BalenAHJacobsHS. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome [see comments]. Fertil Steril. 1994;62(5):921–925.
80.
ZhuWFuZChenXTransvaginal ultrasound-guided ovarian interstitial laser treatment in anovulatory women with polycystic ovary syndrome: a randomized clinical trial on the effect of laser dose used on the outcome. Fertil Steril. 2010;94(1):268–275.
81.
DoneskyBWAdashiEY. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy. Fertil Steril. 1995;63(3):439–463.
82.
EltingMWKorsenTJRekers-MombargLTSchoemakerJ. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15(1):24–28.
83.
EltingMWKweeJKorsenTJRekers-MombargLTSchoemakerJ. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril. 2003;79(5):1154–1160.
84.
AlsamaraiSAdamsJMMurphyMKCriteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009;94(12):4961–4970.
85.
ArmarNAMcGarrigleHHHonourJHolowniaPJacobsHSLachelinGC.Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril. 1990;53(1):45–49.
86.
ChangRJLauferLRMeldrumDRSteroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 1983;56(5):897–903.
87.
LemieuxSLewisGFBen-ChetritASteinerGGreenblattEM. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab. 1999;84(11):4278–4282.
88.
AzzizREhrmannDLegroRSTroglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–1632.
89.
TangTLordJMNormanRJYasminEBalenAH.Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;(1):CD003053.
90.
MiaoZLGuoLWangYXThe intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats. Biomed Environ Sci. 2012;25(1):46–52.
91.
WestERXuMWoodruffTKSheaLD. Physical properties of alginate hydrogels and their effects on in vitro follicle development. Biomaterials. 2007;28(30):4439–4448.
92.
XuMWestESheaLDWoodruffTK. Identification of a stage-specific permissive in vitro culture environment for follicle growth and oocyte development. Biol Reprod. 2006;75(6):916–923.
93.
BaranovaATranTPBirerdincAYounossiZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33(7):801–814.
94.
FernandezIEEickelbergO. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9(3):111–116.
95.
AntoniuSAKolbMR. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs. 2010;13(5):332–345.
96.
DanielsCELaskyJALimperAHMierasKGaborESchroederDR. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181(6):604–610.
97.
RicheldiLCostabelUSelmanMEfficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
98.
CorsonGMCharbonneauNLKeeneDRSakaiLY. Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues. Genomics. 2004;83(3):461–472.
99.
DietzHCLoeysBCartaLRamirezF. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet. 2005;139C(1):4–9.
100.
NeptuneERFrischmeyerPAArkingDEDysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33(3):407–411.
101.
JonesKBMyersLJudgeDPKirbyPADietzHCSponsellerPD. Toward an understanding of dural ectasia: a light microscopy study in a murine model of Marfan syndrome. Spine (Phila Pa 1976). 2005;30(3):291–293.
102.
NgCMChengAMyersLATGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114(11):1586–1592.
103.
HabashiJPJudgeDPHolmTMLosartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–121.
104.
CouckePJWillaertAWesselsMWMutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38(4):452–457.
SuthanthiranMLiBSongJOTransforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000;97(7):3479–3484.
107.
RochaRStierCTJr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12(7):308–314.
108.
WilliamsJS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88(6):2364–2372.
109.
CascellaTPalombaSTauchmanovaLSerum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2006;91(11):4395–4400.
110.
Stetler-StevensonWGAznavoorianSLiottaLA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–573.
WipffPJHinzB. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol. 2008;87(8-9):601–615.
113.
YuQStamenkovicI. Cell surface-localized matrix metall-oproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14(2):163–176.
114.
TaipaleJMiyazonoKHeldinCHKeski-OjaJ. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol. 1994;124(1-2):171–181.
